Testosterone Enanthate 300 mg Cygnus | EPC-0273

52.00€
  • Brand:Cygnus
  • Product Code:EPC-0273
  • Availability:In Stock
Free delivery from 300 euros. Check amount from 200-299 - 25 euros, Check amount up to 199 euros - delivery cost 45 euros.

Pharmacological properties

Testosterone is a hormone of the male sex glands. It has an androgenic, antitumor, and anabolic effect. It affects the development and function of the external genitalia, prostate, seminal vesicles, as well as secondary sexual characteristics (voice, hair). Participates in the formation of the body constitution and sexual behavior, activates libido and potency, stimulates spermatogenesis. It is an antagonist of female sex hormones-estrogens. It has an anabolic effect, which is manifested in stimulating protein synthesis, delaying the necessary potassium, sulfur, phosphorus for protein synthesis, increasing the fixation of calcium in the bones and increasing the muscle mass of the body. Testosterone esters have different rates of absorption and excretion, which ensures a rapid development of the effect and a long-term effect (up to 4 weeks) after a single administration.


Indications for use

Androgen deficiency in men: delayed puberty, oligospermia, post-gastric syndrome, underdevelopment of the genitals, hypopituitrism, infertility in violation of spermatogenesis, menopausal syndrome, impotence of endocrine origin, osteoporosis due to androgen insufficiency. In women: hyperestrogenism, uterine fibroids, endometriosis, menopause (in combination with estrogens), premenstrual tension syndrome, breast cancer, osteoporosis.


Method of application

Only for intramuscular administration. The dosage scheme is selected individually, depending on the disease, gender and age. The usual dosage is 250 mg of testosterone enanthate (1 ampoule) 1 time in 3-4 weeks. In the treatment of hormone-dependent tumors, 250 mg of testosterone enanthate (1 ampoule) is administered 2-3 times a month.


Side effects

From the digestive system: nausea, cholestatic jaundice, increased levels of aminotransferases. Other: edema, hypercalcemia, dizziness, thrombophlebitis. Local reactions: soreness at the injection site, redness and itching. In men: priapism, increased sexual arousal, increased libido and frequent erections, gynecomastia, premature closure of bone epiphyses in prepubescent adolescents. In women: the phenomena of masculinization (virilism) – coarsening of the voice, excessive growth of hair on the face and body, pasty face.


Contraindications

Hypersensitivity, established or suspected prostate and/or breast carcinoma, nephrosis or nephrotic phase of nephritis, hypercalcemia, edema, impaired liver and kidney function, diabetes mellitus, prostatic hypertrophy with symptoms of impaired urination, heart and coronary insufficiency, a history of myocardial infarction, atherosclerosis in older men, pregnancy, breast-feeding.


Drug interaction

Increases the effect of indirect anticoagulants (warfarin, nicumalon, phenyline) and hypoglycemic agents, inhibits the elimination of cyclosporine. Barbiturates and alcohol reduce the effect of testosterone.


Special instructions


With caution, it is used in cases of impaired liver and/or kidney function, heart failure, arterial hypertension, CHD, migraine, epilepsy. In the course of long-term treatment, it is necessary to monitor the condition of the liver. In patients with breast cancer, hypernephroma, lung cancer and bone metastases, careful monitoring of the level of calcium in the blood and urine is necessary. In the treatment of prepubescent adolescents, systematic monitoring is recommended to avoid premature closure of the bone epiphyses, premature puberty. If androgen-dependent adverse reactions occur, treatment is stopped until they disappear and resumed with reduced doses. The drug should be stored out of the reach of children and should not be used after the expiration date.


Overdose

If the drug is used in high doses or for a long time, the side effects described in the corresponding section may develop. In this case, the drug should be discontinued, and after the disappearance of androgen-dependent side effects, continue in smaller doses. If necessary, carry out symptomatic treatment. An overdose of the drug can lead to the cessation of menstruation.

Specifications
Active substance
Testosterone, Testosterone enantato
Active ingredient, mg
300
Release form
Bottle
1 bottle, ml
10
Bottles in the package, pcs
1
Manufacturer
CYGNUS pharmaceuticals group

Write a review

Note: HTML is not translated!
Contact us in any way convenient for you
×